Boston, MA 03\/28\/2014 (wallstreetpr) – The presentation of Northwest Biotherapeutics, Inc (NASDAQ:NWBO) <\/b>top executive Linda Powers in New York had its intended or perhaps default magic in the stock of NWBO. Shares of the biopharma shot up more than 15 percent Thursday. The CEO discussed the company\u2019s product pipeline and addressed DCVax-Direct and DCVax-L. The conference at the New York Academy of Medicine was convened to bring together players \u2013 executives, analysts and investors \u2013 in cancer immunotherapy technology business. The excitement in cancer immunotherapy is having its best impact on NWBO. The company recently landed\u00a0 a rare hospital exemption opportunity in Germany, an approval which is expected to run for five years and whose financial impact can significantly bolster Northwest Biotherapeutics, Inc (NASDAQ:NWBO). The drug that has been granted hospital exemption in Germany is DCVax-L which is currently in its Phase III trial, vying to achieve FDA approval to get to the shelves.<\/p>\n
Orthofix International NV (NASDAQ:OFIX)<\/b> managed to report a decline in revenue in the full-year 2013 compared with 2012. Revenue came in at $400.5 million, lower than the comparable year by 11 percent. The trend was the same in the fourth quarter where net sales came in at $106.1 million, implying 10 percent decrease from the figure realized in the comparable quarter of 2012. However, according to the company management, the seemingly week results are no cause for alarm. The company CEO Brad Mason observed that the company is in a transition mode. And thus, 2013 obviously presented many challenges, yet they are happy they emerged from the year slightly bruised, but stronger to take on 2014 and beyond. The executive confirmed that a lot of behind the scene intrigues ended up in setting Orthofix International NV (NASDAQ:OFIX) on solid path to financial success in 2015 and beyond. Perhaps investors will just have to be a little patient in 2014.<\/p>\n
The gene-based drug and vaccines developer GenVec Inc (NASDAQ:GNVC) <\/b>reports its earnings today. Shares of the company jumped more than 13 percent during trading Thursday as analysts estimated earnings growth. The company is expected, by analyst, to realize about 58 percent jump in EPS compared to the corresponding (fourth) quarter of 2012.<\/p>\n","protected":false},"excerpt":{"rendered":"
Boston, MA 03\/28\/2014 (wallstreetpr) – The presentation of Northwest Biotherapeutics, Inc (NASDAQ:NWBO) top executive Linda Powers in New York had its intended or perhaps default […]<\/p>\n","protected":false},"author":2,"featured_media":18238,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[2236],"tags":[5652,5653,5627,5515,5624,5514],"stock_ticker":[],"class_list":["post-18261","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","tag-genvec-inc-nasdaqgnvc","tag-nasdaqgnvc","tag-nasdaqnwbo","tag-nasdaqofix","tag-northwest-biotherapeutics-inc-nasdaqnwbo","tag-orthofix-international-nv-nasdaqofix","entry"],"acf":[],"yoast_head":"\n